Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.44 |
| ▸ | NPY1R | P25929 | 6/20 | 0.44 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786591 | 0.93 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29732406 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30339921 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30456880 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL1527412 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30945400 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30305284 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL1527410 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30945410 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29732676 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4007592-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LanthioPep B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |